1. Home
  2. HUIZ vs SCYX Comparison

HUIZ vs SCYX Comparison

Compare HUIZ & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huize Holding Limited

HUIZ

Huize Holding Limited

HOLD

Current Price

$3.21

Market Cap

31.5M

Sector

Finance

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.59

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUIZ
SCYX
Founded
2006
1999
Country
China
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.5M
26.3M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
HUIZ
SCYX
Price
$3.21
$0.59
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$2.30
$3.00
AVG Volume (30 Days)
7.8K
366.6K
Earning Date
03-24-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.25
N/A
Revenue
$186,519,166.00
$2,932,000.00
Revenue This Year
$22.67
$167.73
Revenue Next Year
$8.55
$290.78
P/E Ratio
$12.65
N/A
Revenue Growth
19.12
N/A
52 Week Low
$1.50
$0.57
52 Week High
$4.53
$1.49

Technical Indicators

Market Signals
Indicator
HUIZ
SCYX
Relative Strength Index (RSI) 44.38 32.26
Support Level $3.04 $0.58
Resistance Level $3.58 $0.63
Average True Range (ATR) 0.28 0.02
MACD -0.02 -0.00
Stochastic Oscillator 21.88 13.20

Price Performance

Historical Comparison
HUIZ
SCYX

About HUIZ Huize Holding Limited

Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: